TY - JOUR
T1 - Obesity and Psoriatic Arthritis
T2 - A Narrative Review
AU - Kumthekar, Anand
AU - Ogdie, Alexis
N1 - Funding Information:
We acknowledge the support of Dr. Chaim Putterman, Professor of Medicine, Albert Einstein College of Medicine. No funding or sponsorship was received for this study or publication of this article. Dr. Ogdie is supported by NIH/NIAMS R01 AR072363. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published. Anand Kumthekar has nothing to disclose. Alexis Ogdie reports Grants from Novartis (to Penn), Pfizer (To Penn), Amgen (To Forward/NDB); Consulting for AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Corrona, Eli Lilly and Company, Janssen, Novartis, Pfizer, UCB, and Takeda. This article is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors. Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study. This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
Publisher Copyright:
© 2020, The Author(s).
PY - 2020/9/1
Y1 - 2020/9/1
N2 - Patients with psoriatic arthritis (PsA) have a higher burden of cardio-metabolic comorbidities like obesity, hypertension, diabetes, and cardiovascular disease compared to the general population. Adipose tissue is thought to promote a chronic low grade inflammatory state through inflammatory mediators like tumor necrosis factor alpha (TNFα), interleukin-6 (IL-6), leptin, and adiponectin. A higher body mass index (BMI) is a risk factor for development of PsA and affects disease activity and response to therapy including both disease-modifying anti-rheumatic drugs (DMARDs) and tumor necrosis factor inhibitors (TNFi). Obesity has an impact on the morbidity in PsA, particularly cardiovascular and/or metabolic. Patients with PsA have a higher cardiovascular risk and obesity may have an additive impact on morbidity and mortality. This review explores the relationship between obesity and PsA.
AB - Patients with psoriatic arthritis (PsA) have a higher burden of cardio-metabolic comorbidities like obesity, hypertension, diabetes, and cardiovascular disease compared to the general population. Adipose tissue is thought to promote a chronic low grade inflammatory state through inflammatory mediators like tumor necrosis factor alpha (TNFα), interleukin-6 (IL-6), leptin, and adiponectin. A higher body mass index (BMI) is a risk factor for development of PsA and affects disease activity and response to therapy including both disease-modifying anti-rheumatic drugs (DMARDs) and tumor necrosis factor inhibitors (TNFi). Obesity has an impact on the morbidity in PsA, particularly cardiovascular and/or metabolic. Patients with PsA have a higher cardiovascular risk and obesity may have an additive impact on morbidity and mortality. This review explores the relationship between obesity and PsA.
KW - Body mass index (BMI)
KW - Cardiovascular risk
KW - Obesity
KW - Psoriatic arthritis (PsA)
UR - http://www.scopus.com/inward/record.url?scp=85101086479&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85101086479&partnerID=8YFLogxK
U2 - 10.1007/s40744-020-00215-6
DO - 10.1007/s40744-020-00215-6
M3 - Review article
AN - SCOPUS:85101086479
SN - 2198-6576
VL - 7
SP - 447
EP - 456
JO - Rheumatology and Therapy
JF - Rheumatology and Therapy
IS - 3
ER -
